Avid Bioservices (NASDAQ: CDMO)
Q1 2023 | Est. | Actual | Surprise | ||||
---|---|---|---|---|---|---|---|
EPS | (EXPECTED)2022-09-07 | ||||||
REV |
Q4 2022 | Est. | Actual | Surprise | ||||
---|---|---|---|---|---|---|---|
EPS | 0.010 | (EXPECTED) 2022-06-29 | |||||
REV | 28.960M |
Date | Analyst Firm | Analyst Name | Action | Rating | Action Price | Prior Price | Target |
---|
You can purchase shares of Avid Bioservices (NASDAQ: CDMO) through any online brokerage.
Other companies in Avid Bioservices’s space includes: Chinook Therapeutics (NASDAQ:KDNY), Syndax Pharmaceuticals (NASDAQ:SNDX), Replimune Group (NASDAQ:REPL), FibroGen (NASDAQ:FGEN) and Arcutis Biotherapeutics (NASDAQ:ARQT).
The latest price target for Avid Bioservices (NASDAQ: CDMO) was reported by Stephens & Co. on Wednesday, March 9, 2022. The analyst firm set a price target for 28.00 expecting CDMO to rise to within 12 months (a possible 71.25% upside). 7 analyst firms have reported ratings in the last year.
The stock price for Avid Bioservices (NASDAQ: CDMO) is $16.35 last updated Today at June 27, 2022, 8:00 PM UTC.
There are no upcoming dividends for Avid Bioservices.
Avid Bioservices’s Q1 earnings are confirmed for Wednesday, September 7, 2022.
There is no upcoming split for Avid Bioservices.
Avid Bioservices is in the Health Care sector and Biotechnology industry. They are listed on the NASDAQ.